Drugs / CD19-CAR-NK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07243366 | Nov 2025 → Jun 2027 expected | myasthenia gravis | Guangdong ProCapZoom Biosciences Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR-NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07243366 ↗ |
| Modality | Cell therapy | “Allogeneic CD19-CAR-NK cells will be administered intravenously at a fixed dose, once every two weeks for a total treatment duration of 24 weeks.” NCT07243366 ↗ |
| Route | Intravenous | “administered intravenously” NCT07243366 ↗ |
| Target | CD19 | “Allogeneic CD19-CAR-NK cells” NCT07243366 ↗ |